Loading…
← CockpitCompetitor Analysis › ORIC Oric Pharmaceuticals, Inc.Open in the cockpit ↗

Oric Pharmaceuticals, Inc.ORICCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Precision-oncology biotech developing targeted small molecules for prostate cancer and EGFR/HER2-mutant lung cancer.

Momentum laggard 12
Mkt cap
$795M
US dollars, full cap
Free float
66%
of shares outstanding
$/day
$18.1M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-177.0 pp
WACC 11.2%
Hurdle
n/a
no reverse DCF
Next earnings
125 days
23 Mar 2027
Close · USD$7.65
1D-4.4%
1W-15.0%
1M-44.5%
3M-44.9%
6M-9.0%
YTD-6.5%
1Y-36.6%
ATR %10.1%
Beta1.28
52w lowhigh47.9% off high

What Oric Pharmaceuticals does

Precision-oncology biotech developing targeted small molecules for prostate cancer and EGFR/HER2-mutant lung cancer.

Has no approved product, so it earns nothing from sales and pays for trials by selling shares and from cash raised before. Its two lead drugs target prostate cancer and lung cancer with specific gene changes; partnering with a larger drugmaker is the usual route to commercialise later.

Products and services

  • ORIC-944 (prostate cancer, PRC2)
  • ORIC-114 (EGFR/HER2 exon20 NSCLC)

Where it sits in the supply chain

  • Biopharma R&D
  • Targeted oncology drug discovery
  • Resistance-mechanism-focused pipeline

What could go right

  • Positive early clinical data
  • Partnership/licensing interest from big pharma

What could go wrong

  • Early-stage pipeline, binary trial risk
  • Cash runway/dilution risk

Moat: none (IP / patents). Pre-commercial; competes with larger, better-funded oncology programs at bigger companies.

Headquarters: South San Francisco, California, US · Founded: 2017 · Employees: 104

Named competitors

Oric Pharmaceuticals at a glance

Size Oric Pharmaceuticals (ORIC) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $795M, the 2372nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.65 on 18 Nov 2026.

Performance Over six months the shares fell 9.0%, against -5.0% for the median peer and -2.2% for the United States market (cap-weighted) — 8th lowest of 19 in its peer set.

Capital Return on invested capital runs 177.0 points below its cost of capital (11.2% WACC).

Short interest Short interest is 10.3% of the free float (30 Oct 2026).

Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012515017521 May 202621 Aug 202618 Nov 2026Peer median 96ORIC 90
Six months, rebased to 100: Oric Pharmaceuticals against the median of its 20 peers (local-currency closes).

Oric Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$1.13M-$1.22M-$1.11M-$1.03M-$966,000
EBITDA-$170M-$142M-$142M-$110M-$85.8M
Net income-$156M-$129M-$128M-$101M-$89.1M
Free cash flow-$130M-$114M-$114M-$86.8M-$77.6M
Capital expenditure$692,000$712,000$1.19M$849,000$2.08M
Total debt$3.35M$7.44M$9.36M$10.2M$12.1M

Quarterly statements and history in the cockpit →

Oric Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-50%-25%0%+25%SANOFIGUDIRWDRIGL688073SUVEN002349COLLARDX0004116078BLISSGVS0020826032293001ORIC6-month return →1-month return →
Up and to the right = strong over both horizons. Oric Pharmaceuticals is the large dot.

Oric Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (ORIC vs JNJ vs PFE vs AZN.L)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Oric Pharmaceuticals ORIC$795M-9%n/an/an/an/a
Johnson & Johnson JNJ$656B+20%+8%26%6.9×3.7%
Pfizer PFE$160B+9%+1%26%3.3×-4.3%
AstraZeneca AZN.L$278B-2%+5%23%5.0×14.4%

How Oric Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Oric Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureORICPeer medianRank in peer set
1-month return-44.5%-0.9%lowest of 19
6-month return-9.0%-5.0%8th lowest of 19
Distance from 52-week high-47.9%-31.2%4th lowest of 19
ROIC minus cost of capital-177.0 pp-0.5 pplowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Oric Pharmaceuticals ORICUnited States$795M-9%n/an/an/an/an/a
Sanofi India SANOFI.NSIndia$797M0%-6%26%4.1×16.3%-8.7%
Knight Therapeutics GUD.TOCanada$792M+41%+36%6%1.8×6.6%+17.7%
Ironwood Pharmaceuticals IRWDUnited States$791M+22%+18%63%2.6×n/an/a
Bambusa Therapeutics BBTXUnited States$791Mn/an/an/an/an/an/a
Rigel Pharmaceuticals RIGLUnited States$801M+48%+2%26%2.5×1.5%+22.1%
Bide Pharmatech 688073.SSChina$801M+10%+10%19%3.1×13.9%+27.7%
Suven Life Sciences SUVEN.NSIndia$803M-1%+55%-4,452%789.4×n/an/a
Jinghua Pharmaceutical 002349.SZChina$785M-8%+2%20%3.1×-2.5%+2.6%
Collegium Pharmaceutical COLLUnited States$806M-24%+8%15%2.3×-2.6%+20.3%
Ardelyx ARDXUnited States$784M-50%+18%-8%1.6×n/an/a
Zhejiang Int'l 000411.SZChina$783M-21%+3%3%0.3×n/an/a
Hygeia Healthcare 6078.HKHong Kong$811M-3%+2%14%1.8×4.6%+22.5%
Sichuan Neautus Traditional Chinese 2206.HKHong Kong$779Mn/a+7%8%n/an/an/a
Bliss GVS Pharma BLISSGVS.NSIndia$777M+141%+25%18%6.7×33.9%+10.1%
Guizhou Xinbang Pharmaceutical 002390.SZChina$771M-7%-13%4%0.9×-3.8%-0.8%
Wanbangde Pharmaceutical 002082.SZChina$823M-52%-38%-10%7.0×27.7%-39.5%
Zhejiang Ausun Pharmaceutical 603229.SSChina$824M-34%+1%0%6.5×n/an/a
Dezhan Healthcare 000813.SZChina$825M-33%-10%-121%13.8×n/an/a
Lexicon Pharmaceuticals LXRXUnited States$766M-22%-46%-147%16.7×n/an/a
Katakura Industries 3001.TJapan$765M+40%-2%15%2.4×0.3%+0.5%

Questions

Who are Oric Pharmaceuticals's main competitors?
Named competitors: Johnson & Johnson (JNJ), Pfizer (PFE), AstraZeneca (AZN.L). The cockpit's measured peer set (industry) also includes Sanofi India (SANOFI.NS), Knight Therapeutics (GUD.TO), Ironwood Pharmaceuticals (IRWD), Bambusa Therapeutics (BBTX), Rigel Pharmaceuticals (RIGL), Bide Pharmatech (688073.SS).
How has Oric Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -9.0% against -5.0% for the median peer; over one year -36.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.